The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Internal tandem duplications of the FLT3 gene are present in leukemia stem cells.
Mark Levis; Kathleen M Murphy; Rosalyn Pham; Kyu-Tae Kim; Adam Stine; Li Li; Ian McNiece; B Douglas Smith; Donald Small (Profiled Authors: B Smith; Kathleen Murphy; Kathleen Murphy; Donald Small; Li Li; Mark Levis)
Internal tandem duplication mutations of the FLT3 gene (FLT3/ITD mutations) are the most frequent molecular abnormality in acute myeloid leukemia (AML) and are associated with a poor overall survival. While the normal FLT3 receptor is expressed in early hematopoietic progenitor cells, it has not been determined whether FLT3 mutations are present in the leukemic stem cells. In this study, we sorted primary AML samples into stem cell-enriched CD34+/CD38- fractions and then analyzed the sorted and unsorted cells for the FLT3 mutant-wild-type ratio. In each case, the FLT3 mutant-wild-type ratio was not changed by selection of CD34+/CD38- cells, implying that the mutations are present in the leukemic stem cells. We used the stem cell-enriched fraction to engraft nonobese diabetic-severe combined immunodeficient (NOD-SCID) mice and then confirmed that the FLT3/ITD mutation was present in the resultant engrafted marrow. As a final test of the importance of FLT3/ITD signaling in this engraftment model, we used a small molecule FLT3 inhibitor, CEP-701, to inhibit engraftment of FLT3/ITD stem cells. Taken together, these experiments establish that the FLT3/ITD mutations are present in leukemia stem cells, and that FLT3 inhibitors may have activity against these cells.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Jonathan M Gerber; B Douglas Smith; Brownhilda Ngwang; Hao Zhang; Milada S Vala; Laura Morsberger; Steven Galkin; Michael I Collector; Brandy Perkins; Mark J Levis; et al.Blood 2012;119(15):3571-7.
Obdulio Piloto; Mark Levis; David Huso; Yiwen Li; Hongli Li; Mei-Nai Wang; Rajiv Bassi; Paul Balderes; Dale L Ludwig; Larry Witte; et al.
Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice.Cancer research 2005;65(4):1514-22.
R Lumkul; N-C Gorin; M T Malehorn; G T Hoehn; R Zheng; B Baldwin; D Small; S Gore; D Smith; P S Meltzer; et al.Leukemia 2002;16(9):1818-26.
Appears in this Publication
Author of this Publication